RU2011143520A - Способы и композиции для лечения злокачественных опухолей - Google Patents
Способы и композиции для лечения злокачественных опухолей Download PDFInfo
- Publication number
- RU2011143520A RU2011143520A RU2011143520/15A RU2011143520A RU2011143520A RU 2011143520 A RU2011143520 A RU 2011143520A RU 2011143520/15 A RU2011143520/15 A RU 2011143520/15A RU 2011143520 A RU2011143520 A RU 2011143520A RU 2011143520 A RU2011143520 A RU 2011143520A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- composition
- inhibitor
- compound
- acid ceramidase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 29
- 238000000034 method Methods 0.000 title claims 9
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 230000003211 malignant effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 239000003112 inhibitor Substances 0.000 claims abstract 14
- 102000006772 Acid Ceramidase Human genes 0.000 claims abstract 13
- 108020005296 Acid Ceramidase Proteins 0.000 claims abstract 13
- 201000011510 cancer Diseases 0.000 claims abstract 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 8
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract 8
- 229940121737 Choline kinase inhibitor Drugs 0.000 claims abstract 5
- 102000009058 Death Domain Receptors Human genes 0.000 claims abstract 5
- 108010049207 Death Domain Receptors Proteins 0.000 claims abstract 5
- 229940100198 alkylating agent Drugs 0.000 claims abstract 5
- 239000002168 alkylating agent Substances 0.000 claims abstract 5
- 230000000340 anti-metabolite Effects 0.000 claims abstract 5
- 229940100197 antimetabolite Drugs 0.000 claims abstract 5
- 239000002256 antimetabolite Substances 0.000 claims abstract 5
- 239000003446 ligand Substances 0.000 claims abstract 5
- 229910052697 platinum Inorganic materials 0.000 claims abstract 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract 3
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 3
- 102000002745 Choline Kinase Human genes 0.000 claims abstract 2
- 108010018888 Choline kinase Proteins 0.000 claims abstract 2
- 102100031065 Choline kinase alpha Human genes 0.000 claims abstract 2
- 101710106334 Choline kinase alpha Proteins 0.000 claims abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract 2
- 229960004316 cisplatin Drugs 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229960002949 fluorouracil Drugs 0.000 claims abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract 2
- 230000035945 sensitivity Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 3
- 230000000052 comparative effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 102000004201 Ceramidases Human genes 0.000 claims 1
- 108090000751 Ceramidases Proteins 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000011338 personalized therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380270 | 2008-09-17 | ||
| EP08380270.2 | 2008-09-17 | ||
| PCT/EP2009/062078 WO2010031825A2 (en) | 2008-09-17 | 2009-09-17 | Methods and compositions for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011143520A true RU2011143520A (ru) | 2013-05-10 |
Family
ID=40364454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011143520/15A RU2011143520A (ru) | 2008-09-17 | 2009-09-17 | Способы и композиции для лечения злокачественных опухолей |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20100068302A1 (enExample) |
| EP (1) | EP2340042B1 (enExample) |
| JP (1) | JP2012502954A (enExample) |
| KR (1) | KR20110067041A (enExample) |
| CN (1) | CN102215872B (enExample) |
| AU (1) | AU2009294618A1 (enExample) |
| BR (1) | BRPI0919238A2 (enExample) |
| CA (1) | CA2737551A1 (enExample) |
| DK (1) | DK2340042T3 (enExample) |
| ES (1) | ES2527361T3 (enExample) |
| MX (1) | MX2011002956A (enExample) |
| PL (1) | PL2340042T3 (enExample) |
| PT (1) | PT2340042E (enExample) |
| RU (1) | RU2011143520A (enExample) |
| WO (1) | WO2010031825A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| WO2012051415A2 (en) * | 2010-10-13 | 2012-04-19 | Mount Sinai School Of Medicine | Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies |
| EP2468259A1 (en) * | 2010-12-23 | 2012-06-27 | Traslational Cancer Drugs Pharma, S.L. | Pharmaceutical compositions of pyridinium and quinolinium derivatives |
| CA2840129A1 (en) | 2011-06-20 | 2012-12-27 | Traslational Cancer Drugs Pharma, S.L. | Method for predicting the clinical response to chemotherapy in a subject with cancer |
| SI2753346T1 (sl) | 2011-09-07 | 2020-09-30 | Mount Sinai School Of Medicine | Ceramidaza in diferenciacija celic |
| HUE051020T2 (hu) * | 2012-06-01 | 2021-01-28 | Icahn School Med Mount Sinai | A ceramid szintjei a fertõzések kezelésében és megelõzésében |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| WO2014165216A1 (en) * | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Diagnosing and treating cancer |
| WO2014160390A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| KR101537030B1 (ko) * | 2013-08-23 | 2015-07-16 | (주)바이오디펜스 | 천적동물의 눈을 포함한 홀로그램을 이용한 농작물 보호방법 및 그 보호기구 |
| WO2015028662A1 (en) | 2013-08-30 | 2015-03-05 | Consejo Superior De Investigaciones Cientificas (Csic) | Compositions and methods for characterization and amelioration of rheumatoid arthritis |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| EP3439687A1 (en) | 2016-04-07 | 2019-02-13 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| CN107362370B (zh) * | 2016-05-13 | 2022-07-26 | 国家纳米科学中心 | 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法 |
| CN109744199A (zh) * | 2017-11-08 | 2019-05-14 | 南京艾莫瑞生物科技有限公司 | 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用 |
| US12458659B2 (en) * | 2019-02-06 | 2025-11-04 | The Regents Of The University Of California | Methods for treating macrophage-mediated diseases, and methods of identifying agents useful therefore |
| WO2021035168A1 (en) * | 2019-08-22 | 2021-02-25 | Thomas Jefferson University | Methods for reprogramming cancer cells |
| JP7594358B2 (ja) * | 2019-11-29 | 2024-12-04 | 株式会社ダイセル | エクソソーム産生促進剤 |
| CN114644626A (zh) * | 2020-12-18 | 2022-06-21 | 南京施江医药科技有限公司 | 一种苯环类化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830916A (en) * | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
| ES2117950B1 (es) * | 1996-08-02 | 1999-09-16 | Univ Granada | Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular. |
| US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| ES2237332B1 (es) * | 2004-01-14 | 2006-11-01 | Consejo Sup. Investig. Cientificas | Derivados de piridinio y quinolinio. |
| CN1968706A (zh) * | 2004-06-03 | 2007-05-23 | 霍夫曼-拉罗奇有限公司 | 用顺铂和egfr－抑制剂治疗 |
| CN102228689A (zh) * | 2005-04-13 | 2011-11-02 | 科学研究高等机关 | 鉴定用于癌症治疗的化合物的体外方法 |
| ES2277568B1 (es) * | 2005-12-30 | 2008-04-01 | Consejo Superior De Investigaciones Cientificas | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. |
-
2008
- 2008-12-08 US US12/330,190 patent/US20100068302A1/en not_active Abandoned
-
2009
- 2009-09-17 WO PCT/EP2009/062078 patent/WO2010031825A2/en not_active Ceased
- 2009-09-17 PL PL09783138T patent/PL2340042T3/pl unknown
- 2009-09-17 BR BRPI0919238A patent/BRPI0919238A2/pt not_active IP Right Cessation
- 2009-09-17 PT PT97831382T patent/PT2340042E/pt unknown
- 2009-09-17 DK DK09783138.2T patent/DK2340042T3/da active
- 2009-09-17 CN CN200980145259.2A patent/CN102215872B/zh not_active Expired - Fee Related
- 2009-09-17 CA CA2737551A patent/CA2737551A1/en not_active Abandoned
- 2009-09-17 ES ES09783138.2T patent/ES2527361T3/es active Active
- 2009-09-17 AU AU2009294618A patent/AU2009294618A1/en not_active Abandoned
- 2009-09-17 EP EP09783138.2A patent/EP2340042B1/en active Active
- 2009-09-17 JP JP2011527326A patent/JP2012502954A/ja active Pending
- 2009-09-17 US US13/119,488 patent/US20110256241A1/en not_active Abandoned
- 2009-09-17 MX MX2011002956A patent/MX2011002956A/es active IP Right Grant
- 2009-09-17 RU RU2011143520/15A patent/RU2011143520A/ru not_active Application Discontinuation
- 2009-09-17 KR KR1020117008842A patent/KR20110067041A/ko not_active Ceased
-
2011
- 2011-08-12 US US13/209,220 patent/US20120040021A1/en not_active Abandoned
-
2015
- 2015-01-12 US US14/594,860 patent/US20150297576A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT2340042E (pt) | 2014-11-27 |
| PL2340042T3 (pl) | 2015-01-30 |
| CA2737551A1 (en) | 2010-03-25 |
| MX2011002956A (es) | 2011-08-03 |
| US20120040021A1 (en) | 2012-02-16 |
| WO2010031825A2 (en) | 2010-03-25 |
| US20150297576A1 (en) | 2015-10-22 |
| US20100068302A1 (en) | 2010-03-18 |
| EP2340042B1 (en) | 2014-07-23 |
| ES2527361T3 (es) | 2015-01-22 |
| JP2012502954A (ja) | 2012-02-02 |
| US20110256241A1 (en) | 2011-10-20 |
| CN102215872B (zh) | 2015-06-10 |
| DK2340042T3 (da) | 2014-10-27 |
| AU2009294618A2 (en) | 2011-04-14 |
| EP2340042A2 (en) | 2011-07-06 |
| WO2010031825A3 (en) | 2010-08-19 |
| HK1159498A1 (en) | 2012-08-03 |
| AU2009294618A1 (en) | 2010-03-25 |
| CN102215872A (zh) | 2011-10-12 |
| KR20110067041A (ko) | 2011-06-20 |
| BRPI0919238A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011143520A (ru) | Способы и композиции для лечения злокачественных опухолей | |
| JP2012502954A5 (enExample) | ||
| US20240408089A1 (en) | Dosing of kras inhibitor for treatment of cancers | |
| US20230248729A1 (en) | Dosing regimen of kras g12c inhibitor | |
| Lee et al. | Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors | |
| Grünewald et al. | Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models | |
| JP6783224B2 (ja) | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 | |
| CN107849022A (zh) | 取代的喹唑啉化合物和其使用方法 | |
| EP4045047A1 (en) | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers | |
| Petri et al. | New imidazo [2, 1-b][1, 3, 4] thiadiazole derivatives inhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma | |
| CN110507654A (zh) | 有酪氨酸激酶抑制剂的组合产品和其应用 | |
| Lin et al. | Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma | |
| ES2702038T3 (es) | Métodos de tratamiento de fibrosis y cánceres | |
| RU2008138534A (ru) | Фармацевтическая комбинация для лечения и/или хемосенсебилизации опухолей, устойчивых к противораковым средствам | |
| Fang et al. | Targeting strategies for renal cancer stem cell therapy | |
| Pectasides et al. | Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma | |
| Chen et al. | Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells | |
| Xu et al. | Penfluridol inhibits melanoma growth and metastasis through enhancing von Hippel‒Lindau tumor suppressor‐mediated cancerous inhibitor of protein phosphatase 2A (CIP2A) degradation | |
| US12329755B2 (en) | Bromodomain inhibitors to target therapy-resistant cancer | |
| Shi et al. | Treatment for triple-negative breast cancer | |
| AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
| WO2023009701A2 (en) | Therapeutic regimens of a degrader of brd9 | |
| Xie et al. | Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates | |
| RU2809720C2 (ru) | Применение производного инденофлуорена для ингибирования и/или элиминации опухолевых клеток | |
| Dutcher | High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150622 |